NCT06085378尚未招募不适用
Efficacy and Safety of Urinary Kallidinogenase in the Treatment of Acute Ischemic Stroke Combined With Type 2 Diabetes Mellitus (TK-SEEK): a Prospective, Multicenter, Randomized, Double-blind, Placebo-parallel Controlled Study
First Affiliated Hospital, Sun Yat-Sen University1 个研究点 分布在 1 个国家目标入组 630 人开始时间: 2024年1月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 630
- 试验地点
- 1
- 主要终点
- The proportion of patients with modified rankin scale (mRS) 0-2 scores at 90±7 days
研究概览
简要总结
This study is a multicenter, randomized, double-blind, placebo parallel control study, aim to evaluate the efficacy and safety of human urinary kallidinogenase in the treatment of acute ischemic stroke with type 2 diabetes.
详细描述
The study process lasts for a total of 90 days, including the screening period, intervention period, and follow-up period. During the intervention period, the experimental group is treated with Urinary Kallidinogenase, while the control group is treated with placebo for 10 days. Both groups receive routine clinical treatment. All patients are followed up until the 90th day after stroke. The sample size of the study is 630 patients. The ratio of the experimental group to the control group is 1:1.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years old and ≤80 years old;
- •Patients with acute ischemic stroke diagnosed with complete anterior circulation infarction (TACI) and partial anterior circulation infarction (PACI) according to Oxfordshire Community Stroke Project classification (OCSP), see Appendix 6;
- •Refer to the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes (2020 edition), have been diagnosed with type 2 diabetes (need to have a medical history to confirm), see Appendix 7;
- •The time from the occurrence of the stroke to the time of admission is less than 48h. If the exact time of onset is unknown, the time of onset of the patient is defined as "the time that finally seems normal";
- •First-ever ischemic stroke or have history of ischemic stroke but mRS≤1 before onset;
- •6≤NIHSS≤20;
- •Have provided signed written informed consent from the patient or the patient's legal representative
排除标准
- •Acute intracranial hemorrhagic diseases confirmed by imaging: parenchymal hemorrhage, epidural hematoma, subdural hematoma, ventricle hemorrhage, subarachnoid hemorrhage, etc.
- •Patients who are ready to undergo or have undergone intravascular interventional therapy after the onset of the disease;
- •Patients who are ready to undergo or have undergone intravenous thrombolytic therapy after the onset of the disease;
- •Severe disturbance of consciousness: NIHSS 1a consciousness level score ≥2;
- •Patients with fracture, claudication and other factors affecting functional outcome score upon admission;
- •After the onset of the disease, Edaravone injection, Edaravone and Dexborneol concentrated solution for injection, Butylphthalide and sodium chloride injection or Butylphthalide soft capsules have been used;
- •Chinese patent medicine injection for improving cerebral blood circulation has been applied after the onset of this disease (see 8.4.2 for details);
- •Patients with hypotension (blood pressure less than 90/60mmHg) upon admission;
- •Have a history of severe food or drug allergy, or have been allergic to or intolerant of Eurecline injection;
- •Eurecline for injection has used angiotensin-converting enzyme inhibitor (ACEI) drugs before taking the drug and has not exceeded 5 half-lives (according to the specific drug instructions);
- •Patients who are pregnant or breastfeeding and who plan to become pregnant within 90 days;
- •Renal failure or severe renal impairment at the time of screening (creatinine clearance < 30ml/min);
- •Liver function impairment: alanine aminotransferase (ALT), aspartate aminotransferase (AST) > 2.5 times the upper limit of normal, or other known serious liver diseases such as active infection of acute and chronic hepatitis, cirrhosis, etc.;
- •Patients with heart failure (NYHA class III or IV), unstable angina pectoris, acute myocardial infarction, severe arrhythmia, and degree II and III cardiac conduction obstruction within 6 months prior to randomization;
- •Those who meet the heavy drinking standard in the three months before the screening period, that is, drinking ≥5 standard drinks per day (1 standard drink is equivalent to 120ml wine, 360ml beer or 45ml liquor);
- •Patients who have abused or become addicted to drugs (narcotics, drugs) in the past year;
- •Patients with malignant tumors or severe systemic diseases with an expected survival of less than 90 days;
- •Patients with serious mental disorders or dementia who cannot cooperate to complete informed consent and follow-up;
- •Participated in any interventional drug or device clinical trials within 3 months prior to screening;
- •Patients deemed unsuitable for study participation by the investigator;
研究组 & 干预措施
Urinary Kallidinogenase for injection
Experimental
Patients in this arm will be given urinary kallidinogenase for injection, 0.15 peptide nucleic acids(PNA), once a day for 10 days
干预措施: Urinary Kallidinogenase for injection (Drug)
Placebo
Placebo Comparator
An inactive substance identical in appearance to the urinary kallidinogenase for injection, once a day for 10 days
干预措施: Placebo (Other)
结局指标
主要结局
The proportion of patients with modified rankin scale (mRS) 0-2 scores at 90±7 days
时间窗: 90±7 days
The proportion of patients with modified rankin scale (mRS) 0-2 scores at 90±7 days
次要结局
- Changes of NIHSS from baseline to 10 days(from baseline to day 10)
- Changes of mini-mental state examination (MMSE) from baseline to 90±7 days(from baseline to day 90±7)
- Distribution of modified rankin scale (mRS) at 90±7 days(90±7 days)
- Changes of Montreal cognitive assessment (MoCA) from baseline to 90±7 days(from baseline to day 90±7)
- Changes of Barthel index from baseline to 90±7 days(from baseline to day 90±7)
- The proportion of patients with modified rankin scale (mRS) 0-3 scores at 90±7 days(90±7 days)
研究者
Jinsheng Zeng, MD, PhD
Professor
First Affiliated Hospital, Sun Yat-Sen University
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus BacteremiaStaphylococcus Aureus BacteremiaStaphylococcus Aureus EndocarditisNCT03163446ContraFect121
已完成
1 期
Tolerability, Efficacy, and PK of ZSP1601 in Patients With Non-Alcoholic Steatohepatitis (NASH)Non-Alcoholic Steatohepatitis (NASH)NCT04140123Guangdong Raynovent Biotech Co., Ltd37
已完成
2 期
A Dose-finding Study of Silodosin in Patients With Urinary CalculiUrinary CalculusNCT01539265Kissei Pharmaceutical Co., Ltd.300
已完成
2 期
Safety and Efficacy of MK0736 & MK0916 in Patients With Hypertension (High Blood Pressure)(0736-003)(COMPLETED)HypertensionNCT00274716Merck Sharp & Dohme LLC249
已完成
1 期
Safety, Tolerability and PK of SHR1314 in axSpAAxial SpondyloarthritisNCT03704428Jiangsu HengRui Medicine Co., Ltd.45